447 related articles for article (PubMed ID: 30725328)
21. Intracranial Germ Cell Tumors in Adolescents and Young Adults: A 40-Year Multi-Institutional Review of Outcomes.
Lo AC; Hodgson D; Dang J; Tyldesley S; Bouffet E; Bartels U; Cheng S; Hukin J; Bedard PL; Goddard K; Laperriere N
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):269-278. PubMed ID: 31654785
[TBL] [Abstract][Full Text] [Related]
22. How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.
Winter C; Zengerling F; Busch J; Heinzelbecker J; Pfister D; Ruf C; Lackner J; Albers P; Kliesch S; Schmidt S; Bokemeyer C
World J Urol; 2022 Dec; 40(12):2863-2878. PubMed ID: 35554637
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
[TBL] [Abstract][Full Text] [Related]
25. Patterns of care and survival outcomes for adolescent and young adult patients with testicular seminoma in the United States: A National Cancer Database analysis.
Stokes W; Amini A; Maroni PD; Kessler ER; Stokes C; Cost CR; Greffe BS; Garrington TP; Liu AK; Cost NG
J Pediatr Urol; 2017 Aug; 13(4):386.e1-386.e7. PubMed ID: 28153774
[TBL] [Abstract][Full Text] [Related]
26. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
Fizazi K; Oldenburg J; Dunant A; Chen I; Salvioni R; Hartmann JT; De Santis M; Daugaard G; Flechon A; de Giorgi U; Tjulandin S; Schmoll HJ; Bouzy J; Fossa SD; Fromont G
Ann Oncol; 2008 Feb; 19(2):259-64. PubMed ID: 18042838
[TBL] [Abstract][Full Text] [Related]
27. High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases.
Casey DL; Pitter KL; Imber BS; Lin A; Chan TA; Beal K; Yamada Y; Feldman DR; Yang TJ
J Neurooncol; 2019 May; 142(3):523-528. PubMed ID: 30771201
[TBL] [Abstract][Full Text] [Related]
28. French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer.
Murez T; Fléchon A; Branger N; Savoie PH; Rocher L; Camparo P; Neuville P; Ferretti L; Van Hove A; Roupret M
Prog Urol; 2022 Nov; 32(15):1066-1101. PubMed ID: 36400478
[TBL] [Abstract][Full Text] [Related]
29. Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration.
Kildahl-Andersen A; Erke MG; Sagstuen H; Bremnes RM
Acta Oncol; 2005; 44(6):537-44. PubMed ID: 16165912
[TBL] [Abstract][Full Text] [Related]
30. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of testicular germ cell tumors relapse].
Carbonnaux M; Vinceneux A; Peyrat P; Fléchon A
Bull Cancer; 2020 Sep; 107(9):912-924. PubMed ID: 32653158
[TBL] [Abstract][Full Text] [Related]
32. A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer.
Incesu RB; Morra S; Scheipner L; Barletta F; Baudo A; Garcia CC; Tappero S; Piccinelli ML; Tian Z; Saad F; Shariat SF; de Cobelli O; Terrone C; Chun FKH; Carmignani L; Briganti A; Ahyai S; Longo N; Tilki D; Graefen M; Karakiewicz PI
Jpn J Clin Oncol; 2024 May; 54(5):592-598. PubMed ID: 38369557
[TBL] [Abstract][Full Text] [Related]
33. Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long-term events.
Chandran EA; Chindewere A; North R; Jameson MB
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1310. PubMed ID: 33103860
[TBL] [Abstract][Full Text] [Related]
34. Economy of Standards: European Association of Urology Guideline Changes Influence Treatment Costs in Stage I Testicular Cancer Patients.
John A; Baumgart A; Worst T; Heinzelbecker J
Urol Int; 2018; 100(3):279-287. PubMed ID: 29514158
[TBL] [Abstract][Full Text] [Related]
35. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological features and survival of testicular tumours in a Southeast Asian university hospital: a ten-year review.
Tan GH; Azrif M; Shamsul AS; Ho CC; Praveen S; Goh EH; Bahadzor B; Ismail F; Zulkifli MZ
Asian Pac J Cancer Prev; 2011; 12(10):2727-30. PubMed ID: 22320982
[TBL] [Abstract][Full Text] [Related]
37. Multimodality treatment for Central Nervous System Germ Cell Tumors: Disease spectrum and management strategies - A tertiary care center experience from India.
Kumar N; Madan R; Dracham CB; Khosla D; Das N; Dey T; Elangovan A; Tripathi M; Gupta K; Ahuja CK; Kapoor R
Clin Neurol Neurosurg; 2021 Mar; 202():106481. PubMed ID: 33508649
[TBL] [Abstract][Full Text] [Related]
38. [CCAFU french national guidelines 2016-2018 on testicular germ cell tumors].
Durand X; Fléchon A; Murez T; Rocher L; Camparo P; Morel-Journel N; Savoie PH; Ferretti L; Sèbe P; Méjean A
Prog Urol; 2016 Nov; 27 Suppl 1():S147-S165. PubMed ID: 27846929
[TBL] [Abstract][Full Text] [Related]
39. Is there an intermediate-risk non-seminoma? long-term treatment results from a single center.
Cvek J; Feltl D; Hajek J; Jackaninova J; Ruzickova K; Havranek O; Dvorackova J; Dobes P
J BUON; 2014; 19(3):775-9. PubMed ID: 25261666
[TBL] [Abstract][Full Text] [Related]
40. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.
Fankhauser CD; Gerke TA; Roth L; Sander S; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Beyer J; Hermanns T
J Cancer Res Clin Oncol; 2019 Mar; 145(3):781-785. PubMed ID: 30637464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
